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inhibitors (HMGs). OBJECTIVE: The primary objective
is to determine if there are differences among specific
HMGs regarding the incidence of rhabdomyolysis. The
secondary objective is to identify significant risk factors
associated with rhabdomyolysis such as age, gender, and
concurrent gemfibrozil use. METHODS: Retrospective
pharmacy and medical claims from a large managed care
organization were analyzed. Patients were included if
they received any HMG (cerivastatin, fluvastatin, ator-
vastatin, lovastatin, pravastatin, or simvastatin) during
the period between 7/1/99 to 12/31/99. All patients were
followed for 6 months. ICD-9 diagnosis codes for rhab-
domyolysis (idiopathic), myalgia and myositis not other-
wise specified, or adverse effect to antilipemics were used
to define rhabdomyolysis events. RESULTS: There were
133,454 patients identified who received an HMG during
the identification period. The average age was 67.8 years
(S.D.  11.1) and 51.5% were female. The rates of rhab-
domyolysis with and without concurrent gemfibrozil use
were 0.861% and 0.632%, respectively (P  0.13).
Overall, the incidence across individual drugs was similar
for cerivastatin [0.486%(95%CI  0.363%–0.609%)],
fluvastatin [0.679%(95%CI  0.589%–0.769%)], ator-
vastatin [0.889%(95%CI  0.783%–0.995%)], lovasta-
tin [0.741%(95%CI  0.158%–1.332%)], pravastatin
[0.530%(95%CI  0.468%–0.592%)], and simvastatin
[0.378%(95%CI  0.212%–0.544%)]. With concurrent
gemfibrozil use, the incidence was significantly higher for
cerivastatin [6.341%(95%CI  3.005%–9.677%)] com-
pared to fluvastatin [0.713%(95%CI  0.000%–1.439%)],
atorvastatin [0.494%(95%CI  0.062%–0.926%)], lo-
vastatin (0.0%), pravastatin [0.452%(95%CI  0.091%–
0.813%)], and simvastatin (0.0%). In a logistic regres-
sion model, there was no significant relationship between
the incidence of rhabdomyolysis and age or gender.
CONCLUSION: In this population, it appears that the
risk of rhabdomyolysis is substantially higher when ceriv-
astatin is used concurrently with gemfibrozil. The find-
ings of this analysis indicate there is a substantial need
for managed care organizations and pharmacy benefits
management companies to proactively prevent the con-
current use of cerivastatin and gemfibrozil.
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OBJECTIVES: Trials of anticoagulation in non-rheu-
matic atrial fibrillation have demonstrated a reduction in
the risk of stroke by two-thirds. In these trials, the safety
of anticoagulation appeared good, but this may be re-
lated to highly selected patient groups. Exclusion rates of
93% were reported. Participants may have had fewer
complications than might be expected among less se-
lected patients in clinical practice. No trials had actually
looked at the costs of anticoagulation in a real day-to-day
clinical practice. The aim of this study is to investigate
the actual cost of warfarin treatment of atrial fibrillation
in a real clinical practice. METHODS: A one-year retro-
spective study involving patients of all ages admitted to
hospital with non-rheumatic atrial fibrillation on long-
term oral anticoagulation. Patients were interviewed and
their medical records reviewed. The costs of anticoagula-
tion were viewed as follows: 1. The cost of the active
drug. 2. The cost of monitoring the patient’s INR i.e.
traveling costs, staffing cost, and analysis costs. 3. The
costs associated with bleeding complications. RESULTS:
We studied 139 patients. The mean (SD) age was 73.6
(8.9) years, ranging from 41 to 93 years. The mean dura-
tion of oral anticoagulant therapy was 36 months (range
2 to 105 months), forming a total of 417 patient-years of
treatment. Mean (SD) INR was 2.5 (0.36). The target
range of 2.0–3.0 was achieved 54% of the time. Bleeding
occurred in 21 patients, with incidence of 7.2% per pa-
tient-year for minor bleeding, 2.4% per patient-year for
major bleeding and 0.2% for fatal bleeding. The cost of
warfarin tablets was £14.6 ($23.36), per patient-year,
but was £262.6 ($420.16), per patient-year after consid-
ering monitoring and bleeding complication costs. The
cost per stroke prevented was estimated at £8,141
($13,026). CONCLUSION: Anticoagulation appeared
safe and cost-effective in clinical practice but control was
not as good as in clinical trials.
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OBJECTIVES: To evaluate the quality of care given to
older patients hospitalised with heart failure and to iden-
tify areas in which treatment could be improved. METH-
ODS: A two-year retrospective study involving the analy-
sis of the case notes of a random sample of 145 elderly
patients (aged 
75 yrs) admitted to hospital with heart
failure. From The International Classification of Dis-
eases, we identified patients with a principle discharge di-
agnosis of heart failure (ICD codes 428.0-428.1-428.9).
Cases were excluded if the diagnosis could not be vali-
dated by medical record review. A total of one hundred
and forty five patients formed all the admissions with
heart failure during the study period. The standard of
care received was evaluated using the relevant quality of
care indicators derived from the Agency for Health Care
Policy and Research (AHCPR) Clinical Practice Guide-
lines. RESULTS: The study sample included 145 patients.
The mean age (SD) was 82 (5) years. Symptoms and signs
of heart failure were documented in 145 (100%) pa-
tients. All patients with symptoms and signs of hypervol-
aemia received diuretic therapy. Only fifty-five patients
(38%) had an objective assessment of left ventricular
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function by echocardiography. After exclusion of pa-
tients in whom Angiotensin Converting Enzyme (ACE)
inhibitors were contraindicated, only seventy-five (58%)
patients received ACE inhibitors of whom, only 7 (9%)
patients received the target dose recommended by the
clinical practice guidelines. There was no documentation
in the records regarding patient counselling about medi-
cation, diet, weight, exercise or smoking. CONCLU-
SION: ACE inhibitors were underused in elderly patients
with heart failure; also achieving the target dose was
poor. This data demonstrated a very low rate of use of
echocardiography in elderly patients with heart failure.
Counseling appeared to be a neglectedaspect of patient
care.
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OBJECTIVES: Prophylactic anticoagulants, such as low
molecular weight heparin, to prevent thrombosis in hos-
pitalized medical patients has been recommended in clini-
cal guidelines, however the impact on quality adjusted
life years (QALYs) is unclear. This pilot study evaluated
enoxaparin for this indication among elderly (age 59)
hospitalized medical patients. METHODS: Patients were
randomized to receive subcutaneous injections of enox-
aparin 30 mg or placebo daily. Patients who had medical
indications for anticoagulation (e.g., myocardial infarc-
tion, history of thrombosis) were excluded. QALYs were
measured for the period of 30 to 90 days post random-
ization, using the Health Utilities Index(HUI). At 30 and
90 days, 51 and 40 patients in the active group com-
pleted the HUI versus 49 and 36 patients in the placebo
group, respectively. Surveys were received at both time
points among 40 enoxaparin and 21 placebo patients.
QALYs and changes in domain scores were analyzed
over the time between the two surveys. Data were ana-
lyzed using t-tests. RESULTS: Significantly more QALYs
were gained (p  .007)among enoxaparin treated pa-
tients. The mean QALY values were 0.005  0.015 vs
0.008  0.015. The change in the HUI, Mark III do-
main score for ambulation approached significance (p 
0.053. The mean values were 0.012  0.098 for enox-
aparin versus 0.027  0.056 for placebo. A significant
change in the HUI, Mark II domain score for mobility
was found (p  0.017, mean values 0.015  0.064 ver-
sus 0.022  0.050). CONCLUSION: Among medical
patients prophylactic treatment with enoxaparin was as-
sociated with increased QALYs.
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OBJECTIVES: With over one-third of the population
considered to be obese, obesity has reached epidemic pro-
portions in the US The direct costs associated with obe-
sity are currently estimated at about $238 billion. As the
underlying cause of various chronic diseases, obesity neg-
atively impacts quality of life due to impaired physical
and mental well being and reduced daily functions. The
objective of this study is to evaluate the relationship be-
tween obesity and health-related quality of life using the
Centers for Disease Control and Prevention’s (CDC) Be-
havioral Risk Factor Surveillance System (BRFSS) data.
METHODS: The BRFSS is an ongoing, state-based, ran-
dom digit dialed telephone survey of the civilian, non-
institutionalized population aged 3 18 years conducted by
CDC. Data from sixteen states that collected information
on health status (4 items), HRQoL (10 items), and demo-
graphic characteristics including weight and height from
50,454 participants in 1998 were utilized for the analy-
sis. Participants who had a Body Mass Index (BMI) 3 30
were defined as obese. Prevalence of obesity by demo-
graphics and disease presence was determined, as were
corresponding HRQoL scores. RESULTS: On the basis
of BMI, 31.9% of the respondents were identified as
obese. Obesity was higher in males as compared to fe-
males and higher among African-Americans and Hispan-
ics as compared to whites. Obesity increased with age but
decreased as income and education increased. Obese re-
spondents reported poorer health status. Impact of obe-
sity on HRQoL due to reduced physical and mental func-
tioning in the presence of no health problems, as well
as in presence of self-reported major health problems
such as arthritis, cardiovascular disease, diabetes, cancer,
depression, and pulmonary disease is discussed. CON-
CLUSIONS: Health related quality of life is significantly
affected due to obesity and should be an important con-
sideration in the treatment of obesity. It also has impor-
tant implications in case of illnesses that have obesity as
an underlying cause.
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OBJECTIVE: To determine the impact of outpatient an-
ticoagulant/antiplatelet therapy on treatment charges in
